Based on the above pathophysiology, patients with a lower LMR most likely have a higher tumor burden and less cytotoxic T lymphocytes, which may, in part, explain why LMR acts as a prognostic factor in patients with advanced lung cancer who are receiving EGFR-TKIs. This evidence concerns the gene EGFR and lung cancer.